公开(公告)号：US20200069740A1

公开(公告)日：2020-03-05

申请号：US16491974

申请日：2018-03-08

Applicant: ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Hikari Hasegawa ,  Masayo Yumoto ,  Yoshifumi Ikeyama ,  Hiroyuki Nishida ,  Tomohiro Tsuda ,  Eiko Uno ,  Kazuma Suda ,  Mihoko Yoshino ,  Xuan Trung Ngo

IPC: A61K35/28

Abstract: The purpose of the present invention is to provide the following: novel mesenchymal stem cells having an excellent therapeutic effect on various diseases, particularly diseases associated with fibrosis; and a pharmaceutical composition containing such mesenchymal stem cells. The present invention is a therapeutic agent for fibrosis that contains ROR1-positive mesenchymal stem cells and/or a culture supernatant thereof and that is for preventing or treating a disease associated with fibrosis. The mesenchymal stem cells are CD29-, CD73-, CD90-, CD105-, and CD166-positive and are preferably derived from the umbilical cord or fat. In addition, the abovementioned disease associated with fibrosis is preferably a liver disease, a lung disease, a kidney disease, or a heart disease.

公开(公告)号：US20190117701A1

公开(公告)日：2019-04-25

申请号：US16096973

申请日：2017-04-27

Applicant: ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Yoshifumi Ikeyama ,  Eiko Uno ,  Masayo Yumoto ,  Mihoko Yoshino ,  Xuan Trung Ngo ,  Hiroyuki Nishida ,  Akiko Uetani

IPC: A61K35/28 ,  A61P29/00

Abstract: An object of the present invention is to provide novel mesenchymal stem cells demonstrating superior therapeutic effects for various diseases, a novel pharmaceutical composition containing the mesenchymal stem cells, and methods for preparing these. The present invention provides mesenchymal stem cells expressing at least one cell surface marker selected from the group consisting of CD201, CD46, CD56, CD147 and CD165. The mesenchymal stem cells expressing such a specific marker are positive for CD29, CD73, CD90, CD105 and CD166, and maintain an undifferentiated state.

公开(公告)号：US11707488B2

公开(公告)日：2023-07-25

申请号：US15755859

申请日：2016-08-29

Applicant: ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Yoshifumi Ikeyama ,  Hiroyuki Nishida ,  Tomohiro Tsuda ,  Eiko Uno ,  Masayo Yumoto ,  Kazuma Suda ,  Mihoko Yoshino ,  Xuan Trung Ngo

IPC: A61K35/28 ,  C12N5/0775

CPC classification number: A61K35/28 ,  C12N5/0662 ,  C12N2501/998 ,  C12N2510/00 ,  Y02A50/30

Abstract: An object of the present invention is to provide novel mesenchymal stem cells demonstrating superior therapeutic effects against various diseases, a novel pharmaceutical composition containing these mesenchymal stem cells, and a method for preparing the same. The present invention relates to ROR1-positive mesenchymal stem cells. The ROR1-positive mesenchymal stem cells are preferably positive for CD29, CD73, CD90, CD105 and CD166 and are derived from umbilical cord or adipose tissue.

公开(公告)号：US11179420B2

公开(公告)日：2021-11-23

申请号：US16096973

申请日：2017-04-27

Applicant: ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Yoshifumi Ikeyama ,  Eiko Uno ,  Masayo Yumoto ,  Mihoko Yoshino ,  Xuan Trung Ngo ,  Hiroyuki Nishida ,  Akiko Uetani

IPC: C12N5/0775 ,  A61K35/28 ,  A61P29/00

Abstract: An object of the present invention is to provide novel mesenchymal stem cells demonstrating superior therapeutic effects for various diseases, a novel pharmaceutical composition containing the mesenchymal stem cells, and methods for preparing these. The present invention provides mesenchymal stem cells expressing at least one cell surface marker selected from the group consisting of CD201, CD46, CD56, CD147 and CD165. The mesenchymal stem cells expressing such a specific marker are positive for CD29, CD73, CD90, CD105 and CD166, and maintain an undifferentiated state.

公开(公告)号：US20180333436A1

公开(公告)日：2018-11-22

申请号：US15755859

申请日：2016-08-29

Applicant: ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Yoshifumi Ikeyama ,  Hiroyuki Nishida ,  Tomohiro Tsuda ,  Eiko Uno ,  Masayo Yumoto ,  Kazuma Suda ,  Mihoko Yoshino ,  Xuan Trung Ngo

IPC: A61K35/28 ,  C12N5/0775

CPC classification number: A61K35/28 ,  C12N5/0662 ,  C12N2501/998 ,  C12N2510/00 ,  Y02A50/411

Abstract: An object of the present invention is to provide novel mesenchymal stem cells demonstrating superior therapeutic effects against various diseases, a novel pharmaceutical composition containing these mesenchymal stem cells, and a method for preparing the same. The present invention relates to ROR1-positive mesenchymal stem cells. The ROR1-positive mesenchymal stem cells are preferably positive for CD29, CD73, CD90, CD105 and CD166 and are derived from umbilical cord or adipose tissue.